Primary cells are another option which have much higher TEER and lower permeability than the available cell lines, but they are more time consuming, expensive, and can be passaged a limited number of times
Eur Respir Rev 2023;32:230015
Recent Pat Anti-Cancer Drug Discov 7(1):6473 Kubickova L, Brazda P, Veverka M, Kaman O, Herynek V, Vosmanska M, Dvorak P, Bernasek K, Kohout J (2019) Nanomagnets for ultra-high field MRI: magnetic properties and transverse relaxivity of silica-coated epsilon-Fe2O3
General purpose molecular dynamics simulations fully implemented on graphics processing units
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Key Points Summary Asias GLP1 uptake has lagged the West but is primed for rapid acceleration as obesity rates rise and government urgency grows China and India are driving demand shifts as diets westernise and metabolic disease climbs Cost barriers are falling: local firms in China and India are developing cheaper semaglutide generics, forcing price cuts Mintel forecasts explosive growth, with China potentially becoming the worlds No1 GLP1 market by 2030 Safety fears persist in China (side effects, rebound, semaglutide face) and in India (strict rules on drug promotion) GLP-1 agonist drugs have revolutionised weight loss in the United States and parts of Europe, providing in most cases a highly effective way to manage the ballooning issue of obesity in these markets
-1775582746855.png&w=384&q=75)
